Latest Manufacturing Processes News

Mesoblast Limited is set to release its full-year financial results and operational highlights for 2025, spotlighting its FDA-approved cell therapy and expanding global partnerships.

Mayfield Group Holdings Ltd has reported a landmark financial year with revenues soaring nearly 38% and profits climbing over 32%, driven by strong demand in Data Centres and AI infrastructure sectors.

First Graphene Limited’s partnership with Halocell Energy and QUT has yielded a breakthrough in perovskite solar cells, doubling efficiency to 30.6% while cutting production costs by up to 80%. This innovation paves the way for scalable, low-cost solar solutions across multiple industries.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

AdAlta Limited outlines its innovative 'East to West' cellular immunotherapy approach, in-licensing Asian CAR-T assets and progressing clinical trials in Australia to unlock value. The company also seeks partners for its anti-fibrotic and anti-malarial protein therapeutics.

Adrad Holdings reported an 8.9% rise in FY25 sales revenue to $153.1 million despite a slight dip in EBITDA, while declaring a fully franked dividend and outlining strategic initiatives for FY26.

Archer Materials has partnered with Belgium’s IMEC to develop a scalable, cost-effective potassium ion biosensor using silicon semiconductor technology, aiming to accelerate commercial production by late 2025.

LTR Pharma has initiated commercial distribution of its nasal spray SPONTAN through Australia's Symbion pharmacy network and is advancing ROXUS development for a US launch in early 2026, while expanding its pipeline with a new intranasal treatment for swallowing disorders.

Arovella Therapeutics reported a robust $20.9 million cash position as it prepares for its first-in-human trial of ALA-101 and expands its solid tumour pipeline through new licensing agreements and leadership appointments.

ClearVue Technologies has appointed Douglas Hunt as its permanent Global CEO, unveiling a refreshed leadership team focused on scaling sales, manufacturing, and product innovation. The new executives have agreed to sub-market pay until the share price hits 35 cents, signaling strong alignment with shareholder interests.

Imagion Biosystems has received encouraging feedback from the FDA on its MagSense HER2 breast cancer imaging program, clearing the path for a Phase 2 clinical trial and fast-tracking manufacturing.

Wide Open Agriculture has achieved a breakthrough in lupin protein production, slashing energy consumption by up to 80% and halving processing time in a recent commercial-scale trial. These efficiency gains pave the way for more cost-effective, scalable manufacturing.